Pterostilbene appears to selectively target the hippocampus region in the brain. There, it increases brain-derived neurotrophic factor (BDNF), mitogen-activated protein kinases (MAPK), and cAMP response element binding protein (CREB). These three proteins help neurons grow, multiply, and respond to their surroundings. SNRI antidepressants often target these pathways as well. Also in the hippocampus, pterostilbene increases a protein called Nrf2, which in turn increases the expression of antioxidant proteins.
Pterostilbene ເບິ່ງຄືວ່າຈະຄັດເລືອກເປົ້າຫມາຍຂອງເຂດ hippocampus ໃນສະຫມອງ. ໃນນັ້ນ, ມັນເພີ່ມທະວີປັດໄຈທາງ neurotrophic ຈາກສະຫມອງ (BDNF), ໂປຕີນ kinases mitogen-activated (MAPK), ແລະທາດປະສົມ binding binding protein CAMP (CREB). ທາດໂປຼຕີນເຫຼົ່ານີ້ສາມຊ່ວຍ neurons ຂະຫຍາຍຕົວ, ເພີ່ມແລະຕອບສະຫນອງຕໍ່ສິ່ງແວດລ້ອມຂອງພວກມັນ. SNRI antidepressants ມັກຈະແນເປົ້າໃສ່ເສັ້ນທາງເຫຼົ່ານີ້ເຊັ່ນດຽວກັນ. ນອກຈາກນີ້ໃນ hippocampus, pterostilbene ເພີ່ມທາດໂປຼຕີນທີ່ເອີ້ນວ່າ Nrf2, ເຊິ່ງເຮັດໃຫ້ການສະແດງອອກຂອງທາດໂປຼຕີນຈາກ antioxidant ເພີ່ມຂຶ້ນ.